Skip to main content

Table 1 Patients’ background

From: Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer

 

Control group (n = 52)

Aprepitant group (n = 54)

P-value

Age (median, range)

59 (29–83)

58 (38–81)

0.70

Performance status (ECOG)

0–1/2–3

51/1

53/1

1.00

Cancer diagnosis (number, %)

 Ovarian or tubal cancer

17 (32.7)

22 (40.7)

0.43

 Uterine cancer

28 (53.8)

28 (51.9)

0.85

 Cervical cancer

6 (11.5)

1 (1.9)

0.06

 Vaginal cancer

0 (0)

1 (1.9)

1.00

 Double cancer

1 (1.9)

2 (3.7)

1.00

Staging (number, %)

 I/II/III

39 (75.0)

39 (72.2)

0.83

 IV/recurrence

13 (25.0)

15 (27.8)

Chemotherapy setting

 neoadjuvant or adjuvant

44 (84.6)

49 (90.7)

0.34

 for advanced cancer

8 (15.4)

5 (9.3)

Height (cm)

(median, range)

155.5 (144.6–172.1)

154.2 (142.0–169.5)

0.49

Body weight (kg)

(median, range)

54.7 (35.6–84.6)

54.3 (37.7–89.2)

0.79

Body surface area (m2)

(median, range)

1.53 (1.24–1.85)

1.54 (1.21–1.87)

0.90

Drinking habit (number, %)

24 (46.2)

21 (38.9)

0.57

Carboplatin dosage (AUC) (number, %)

 5

52 (100)

53 (98.1)

1.00

 6

0 (0)

1 (1.9)

Paclitaxel dosage (mg)

(median, range)

261.7 (220–320)

266.8 (210–325)

0.43

Dose reduction

(number, %)

3 (5.8)

1 (1.9)

0.36

Renal dysfunction

(number, %)

4 (7.6)

5 (9.3)

1.00

Liver dysfunction

(number, %)

9 (17.3)

12 (22.2)

0.63

  1. Renal dysfunction: grade 1 or higher serum creatinine elevation
  2. Liver dysfunction: grade 1 or higher aspartate transaminase, alanine aminotransferase, and total bilirubin elevation
  3. AUC area under the carve